24/7 Market News Snapshot 29 October, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

October 29, 2024

DENVER, Colo., 29 October, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) has recently experienced a notable surge in its stock value, opening at $0.89 and climbing to a current trading price of $1.157, marking a significant 31.48% increase from the previous session closing at $0.880. This upswing reflects strong investor interest and a positive outlook on the stock’s performance, highlighted by a trading volume of 1.72 million shares. Technical indicators suggest a prevailing bullish trend, positioning Hoth for potential further growth if momentum persists.

Simultaneously, Hoth Therapeutics is making strides in the biopharmaceutical landscape with the announcement of preliminary results from a preclinical study of its innovative cancer treatment, conducted in collaboration with NC State University. The study reveals promising data that indicates the treatment’s effectiveness in stabilizing tumor growth. Researchers meticulously measured tumor volumes in both treated and untreated groups, with treated subjects demonstrating minimal tumor size changes, signifying a robust inhibitory effect on cancer progression.

The consistency observed in treated tumors, characterized by nearly invisible standard deviation error bars, underscores the reproducibility of the treatment’s effects. Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm regarding these results, stating, “The stabilization of tumor growth demonstrates the potential of our treatment as a viable option for patients battling cancer.” The contrast in growth variability between treated and untreated subjects further emphasizes the efficacy of the therapy.

As Hoth Therapeutics continues to advance its research, the company is optimistic about the implications of these findings in delivering impactful cancer therapies, reinforcing its commitment to addressing unmet medical needs in oncology. The promising results could pave the way for further testing and eventual clinical applications.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.